Morgan Stanley Upgrades Novo Nordisk to Equal Weight Amid Improved Growth Trajectory

Morgan Stanley has upgraded Novo Nordisk A/S (NVO) to Equal Weight from Underweight, signaling a revised outlook on the Danish pharmaceutical giant. The change follows a series of positive developments in Novo Nordisk’s pipeline, particularly in its GLP-1-based therapies, which continue to demonstrate robust clinical performance in Phase 3 trials for type 2 diabetes and obesity. The firm highlighted the company’s expanding global footprint, with new market entries in Southeast Asia and Latin America contributing to revenue diversification. Key metrics underpinning the upgrade include NVO’s 2025 revenue guidance of $42.3 billion, which reflects a 17% year-over-year increase, driven by sustained demand for Wegovy and Ozempic. Additionally, the company reported a 23% rise in R&D investment during the last fiscal year, with $3.4 billion allocated to late-stage development programs. Analysts note that the company’s gross margin remains above 82%, underscoring strong pricing power and operational efficiency. While the upgrade is not expected to trigger immediate market volatility, it signals growing confidence in Novo Nordisk’s ability to maintain double-digit growth through 2027. The reclassification may influence passive investment flows, particularly for funds tracking the S&P 500 or MSCI World Health Care Index, where NVO is a significant constituent. Institutional investors may reassess positioning in light of the improved fundamental outlook. The move underscores increasing investor focus on long-term biopharmaceutical innovation, particularly in metabolic diseases. With NVO’s market cap exceeding $1.2 trillion as of March 2026, the upgrade reflects broader sentiment around scalable, science-driven growth in the healthcare sector.